These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36346290)

  • 1. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
    Alcaraz LB; Mallavialle A; Mollevi C; Boissière-Michot F; Mansouri H; Simony-Lafontaine J; Laurent-Matha V; Chardès T; Jacot W; Turtoi A; Roger P; Guiu S; Liaudet-Coopman E
    Int J Cancer; 2023 Mar; 152(6):1243-1258. PubMed ID: 36346290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
    Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
    Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
    [No Abstract]   [Full Text] [Related]  

  • 3. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.
    Zhu A; Yuan P; Du F; Hong R; Ding X; Shi X; Fan Y; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B
    Oncotarget; 2016 Nov; 7(47):76628-76634. PubMed ID: 27421134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
    Front Immunol; 2019; 10():757. PubMed ID: 31031757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the association of POSTN
    Lin S; Zhou M; Cheng L; Shuai Z; Zhao M; Jie R; Wan Q; Peng F; Ding S
    Int J Biol Macromol; 2024 May; 268(Pt 1):131560. PubMed ID: 38631570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
    Broad RV; Jones SJ; Teske MC; Wastall LM; Hanby AM; Thorne JL; Hughes TA
    Br J Cancer; 2021 Mar; 124(6):1110-1120. PubMed ID: 33398063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
    Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
    BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer.
    Zheng S; Zou Y; Tang Y; Yang A; Liang JY; Wu L; Tian W; Xiao W; Xie X; Yang L; Xie J; Wei W; Xie X
    Oncoimmunology; 2022; 11(1):2020984. PubMed ID: 35003899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of the expression of cancer-associated fibroblast markers in esophageal cancer with and without neoadjuvant therapy.
    Galván JA; Wiprächtiger J; Slotta-Huspenina J; Feith M; Ott K; Kröll D; Seiler CA; Langer R
    Virchows Arch; 2020 May; 476(5):725-734. PubMed ID: 31828432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a tumor-associated fibroblast associated gene score based on scRNA-seq to predict prognosis in patients with triple-negative breast cancer.
    Yu H; Peng Z; Li X; Zhang Y
    PLoS One; 2024; 19(10):e0311801. PubMed ID: 39418248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
    Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
    J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Qian XL; Xu P; Zhang YQ; Song YM; Li YQ; Li WD; Jiang CY; Shen BB; Zhang XM; Zhang LN; Fu L; Guo XJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):311-319. PubMed ID: 31993861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.